Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes [TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT]

CONCLUSIONS The 30-day outcomes following implantation of the HeartMate 3 demonstrates excellent survival with low adverse event rates. The LVAD performed as intended with no haemolysis or device failure. CLINICALTRIALS.GOV IDENTIFIER NCT02170363. HeartMate 3™ CE Mark Clinical Investigation Plan (HM3 CE Mark).

http://ejcts.oxfordjournals.org/cgi/content/short/50/3/548?rss=1

Source: European Journal of Cardio-Thoracic Surgery - August 30, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Zimpfer, D., Netuka, I., Schmitto, J. D., Pya, Y., Garbade, J., Morshuis, M., Beyersdorf, F., Marasco, S., Rao, V., Damme, L., Sood, P., Krabatsch, T. Tags: Minimally invasive surgery, Myocardial protection, Peripheral vascular TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT Source Type: research